216 related articles for article (PubMed ID: 22571785)
21. Phosphodiesterases in the vascular system.
Matsumoto T; Kobayashi T; Kamata K
J Smooth Muscle Res; 2003 Aug; 39(4):67-86. PubMed ID: 14692693
[TBL] [Abstract][Full Text] [Related]
22. Improving memory: a role for phosphodiesterases.
Blokland A; Schreiber R; Prickaerts J
Curr Pharm Des; 2006; 12(20):2511-23. PubMed ID: 16842174
[TBL] [Abstract][Full Text] [Related]
23. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterases as therapeutic targets for respiratory diseases.
Zuo H; Cattani-Cavalieri I; Musheshe N; Nikolaev VO; Schmidt M
Pharmacol Ther; 2019 May; 197():225-242. PubMed ID: 30759374
[TBL] [Abstract][Full Text] [Related]
25. In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654.
Barret O; Thomae D; Tavares A; Alagille D; Papin C; Waterhouse R; McCarthy T; Jennings D; Marek K; Russell D; Seibyl J; Tamagnan G
J Nucl Med; 2014 Aug; 55(8):1297-304. PubMed ID: 24898025
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and their ratios between high- and low-affinity rolipram binding.
Hsu HT; Wang WH; Han CY; Chen CN; Chen CM; Ko WC
J Pharm Sci; 2013 Jul; 102(7):2120-7. PubMed ID: 23666855
[TBL] [Abstract][Full Text] [Related]
27. The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET).
Banister SD; Manoli M; Kassiou M
J Labelled Comp Radiopharm; 2013; 56(3-4):215-24. PubMed ID: 24285328
[TBL] [Abstract][Full Text] [Related]
28. Advances, Perspectives and Potential Engineering Strategies of Light-Gated Phosphodiesterases for Optogenetic Applications.
Tian Y; Yang S; Gao S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066112
[TBL] [Abstract][Full Text] [Related]
29. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
30. Application of Free Energy Perturbation (FEP+) to Understanding Ligand Selectivity: A Case Study to Assess Selectivity Between Pairs of Phosphodiesterases (PDE's).
Moraca F; Negri A; de Oliveira C; Abel R
J Chem Inf Model; 2019 Jun; 59(6):2729-2740. PubMed ID: 31144815
[TBL] [Abstract][Full Text] [Related]
31. In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.
Kenk M; Greene M; Thackeray J; deKemp RA; Lortie M; Thorn S; Beanlands RS; DaSilva JN
Nucl Med Biol; 2007 Jan; 34(1):71-7. PubMed ID: 17210463
[TBL] [Abstract][Full Text] [Related]
32. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.
Cox CD; Hostetler ED; Flores BA; Evelhoch JL; Fan H; Gantert L; Holahan M; Eng W; Joshi A; McGaughey G; Meng X; Purcell M; Raheem IT; Riffel K; Yan Y; Renger JJ; Smith SM; Coleman PJ
Bioorg Med Chem Lett; 2015 Nov; 25(21):4893-4898. PubMed ID: 26077491
[TBL] [Abstract][Full Text] [Related]
33. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
34. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation.
Essayan DM
Biochem Pharmacol; 1999 May; 57(9):965-73. PubMed ID: 10796066
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
[TBL] [Abstract][Full Text] [Related]
36. A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study.
Lau JK; Li XB; Cheng YK
J Phys Chem B; 2010 Apr; 114(15):5154-60. PubMed ID: 20349929
[TBL] [Abstract][Full Text] [Related]
37. Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?
Nthenge-Ngumbau DN; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):822-834. PubMed ID: 28062949
[TBL] [Abstract][Full Text] [Related]
38. Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers?
Joshi EM; Need A; Schaus J; Chen Z; Benesh D; Mitch C; Morton S; Raub TJ; Phebus L; Barth V
ACS Chem Neurosci; 2014 Dec; 5(12):1154-63. PubMed ID: 25247893
[TBL] [Abstract][Full Text] [Related]
39. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
